SLC30A1 and colon adenocarcinoma: For comparison, in thyroid cancer, ovarian cancer, brain glioma, glioblastoma, and colon adenocarcinoma, where ZnT1 transcript levels were not significantly different, patient survival rates did not differ (Fig. 2c).